Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 28;12(5):1898.
doi: 10.3390/jcm12051898.

Acute Kidney Injury in the ICU during Ganciclovir Treatment, an Observational Study

Mina Al Fartousi  1 , Kaylen Guda  1 , Tjerk H Geersing  1 , Peter H J van der Voort  2   3   4 , Eric J F Franssen  1
Affiliations

Acute Kidney Injury in the ICU during Ganciclovir Treatment, an Observational Study

Mina Al Fartousi et al. J Clin Med. .

Abstract

The aim of this study is to investigate the relationship between ganciclovir exposure with TDM and the development of AKI in ICU patients. This retrospective single-center observational cohort study included adult ICU patients treated with ganciclovir who had a minimum of one ganciclovir trough serum level. Patients receiving less than two days of treatment and patients with fewer than two measurements of serum creatinine, RIFLE scores, and/or renal SOFA scores were excluded. Acute kidney injury incidence was assessed with the difference between the final and first values of the renal SOFA score, RIFLE score, and serum creatinine. Nonparametric statistical tests were performed. In addition, the clinical relevance of these results was evaluated. A total of 64 patients were included with a median cumulative dose of 3150 mg. The mean difference in serum creatinine during ganciclovir treatment was reduced by 7.3 μmol/L (p = 0.143). The RIFLE score decreased by 0.04 (p = 0.912), and the renal SOFA score was reduced by 0.07 (p = 0.551). This single-center observational cohort study showed that ICU patients using ganciclovir with TDM-guided dosing did not develop acute kidney injury as measured by serum creatinine, RIFLE score, and renal SOFA score.

Keywords: ICU; acute kidney injury; cytomegalovirus; ganciclovir; therapeutic drug monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient enrolment.
Figure 2
Figure 2
Impact of cumulative ganciclovir dose on the change in serum creatinine.
Figure 3
Figure 3
Impact of cumulative ganciclovir dose on the change in RIFLE score.
Figure 4
Figure 4
Impact of cumulative ganciclovir dose on the change in renal sofa score.
See this image and copyright information in PMC

References

    1. Cannon M.J., Schmid D.S., Hyde T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol. 2010;20:202–213. doi: 10.1002/rmv.655. - DOI - PubMed
    1. Florescu D.F., Kalil A.C. Cytomegalovirus infections in non-immunocompromised and immunocompromised patients in the intensive care unit. Infect. Disord. Drug. Targets. 2011;11:354–364. doi: 10.2174/187152611796504773. - DOI - PubMed
    1. LCI-richtlijn van het RIVM. Rivm.nl. [(accessed on 3 March 2021)]. Available online: https://lci.rivm.nl/richtlijnen/cmv-infectie.
    1. Mody H., Ramakrishnan V., Chaar M., Lezeau J., Rump A., Taha K., Lesko L., Ait-Oudhia S. A review on drug-induced nephrotoxicity: Pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches. Clin. Pharmacol. Drug. Dev. 2020;9:896–909. doi: 10.1002/cpdd.879. - DOI - PubMed
    1. Huntjens D.W., Dijkstra J.A., Verwiel L.N., Slijkhuis M., Elbers P., Welkers M.R.A., Veldkamp A.I., Kuijvenhoven M.A., de Leeuw D.C., Abdullah-Koolmees H., et al. Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients. Pharmaceutics. 2023;15:163. doi: 10.3390/pharmaceutics15010163. - DOI - PMC - PubMed

LinkOut - more resources